Evidence map›Paper›PMID 30235809›Full record

ReviewInternational journal of molecular sciences2018

Ocular Drug Delivery: Role of Degradable Polymeric Nanocarriers for Ophthalmic Application.

Cheng-Han Tsai, Peng-Yuan Wang, I-Chan Lin, Hu Huang, Guei-Sheung Liu, Ching-Li Tseng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats.Journal of visualized experiments : JoVE · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Cheng-Han TsaiGraduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan. m825105004@tmu.edu.tw.ORCID 0000-0003-4058-834X
Peng-Yuan WangCenter for Human Tissues and Organs Degeneration, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China. py.wang@siat.ac.cn.
I-Chan LinDepartment of Ophthalmology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan. ichanlin@gmail.com.
Hu HuangAier Eye Institute; Aier School of Ophthalmology, Central South University, Changsha 410008, China. huanghu@aierchina.com.
Guei-Sheung LiuMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia. rickliu0817@gmail.com.ORCID 0000-0003-3379-724X
Ching-Li TsengGraduate Institute of Biomedical Materials & Tissue Engineering, College of Biomedical Engineering, Taipei Medical University, Taipei 11031, Taiwan. chingli@tmu.edu.tw.ORCID 0000-0001-9446-4030

Funding

Ministry of Science and Technology, Taiwan MOST 106-2628-E-038 -001 -MY3Ministry of Science and Technology, Taiwan MOST 107-2628-E-038 -001 -MY3National Health and Medical Research Council 1061912Rebecca L. Cooper Medical Research Foundation n/aThe Ophthalmic Research Institute of Australia n/a
6 · The paper itself

Abstract

Ocular drug delivery has been a major challenge for clinical pharmacologists and biomaterial scientists due to intricate and unique anatomical and physiological barriers in the eye. The critical requirement varies from anterior and posterior ocular segments from a drug delivery perspective. Recently, many new drugs with special formulations have been introduced for targeted delivery with modified methods and routes of drug administration to improve drug delivery efficacy. Current developments in nanoformulations of drug carrier systems have become a promising attribute to enhance drug retention/permeation and prolong drug release in ocular tissue. Biodegradable polymers have been explored as the base polymers to prepare nanocarriers for encasing existing drugs to enhance the therapeutic effect with better tissue adherence, prolonged drug action, improved bioavailability, decreased toxicity, and targeted delivery in eye. In this review, we summarized recent studies on sustained ocular drug/gene delivery and emphasized on the nanocarriers made by biodegradable polymers such as liposome, poly lactic-co-glycolic acid (PLGA), chitosan, and gelatin. Moreover, we discussed the bio-distribution of these nanocarriers in the ocular tissue and their therapeutic applications in various ocular diseases.

Indexed as

Administration, OphthalmicOcular AbsorptionAnimalsBiodegradable PlasticsDrug CarriersHumansInjections, IntraocularNanoparticlesBiodegradable PlasticsDrug Carriersanteriorbiodegradabledrug/gene deliverynanoparticlesocularpolymericposterior

Identifiers

PMID30235809
PMCPMC6164366

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.